𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease

✍ Scribed by Ramón Peces; Emilio Cuesta-López; Carlos Peces; Virginia Pérez-Dueñas; Cristina Vega-Cabrera; Rafael Selgas

Publisher
Springer Netherlands
Year
2010
Tongue
English
Weight
305 KB
Volume
43
Category
Article
ISSN
0301-1623

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk factors for the development of hepa
Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease
✍ Patricia A. Gabow; Ann M. Johnson; William D. Kaehny; Michael L. Manco-Johnson; 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 582 KB

Hepatic cysts are a major manifestation of autosomal dominant polycystic kidney disease. This study examined 239 autosomal dominant polycystic kidney disease patients and 189 unaffected family members to define the factors that influence the presence and severity of hepatic cysts. Autosomal dominant

Postmenopausal estrogen therapy selectiv
Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease
✍ R Sherstha; C McKinley; P Russ; A Scherzinger; T Bronner; R Showalter; G T Evers 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB

The goal of this study was to determine whether use of postmenopausal estrogen (Premarin, Wyeth-Ayerst, Philadelphia, PA) in women with autosomal dominant polycystic kidney disease (ADPKD) increases liver, hepatic cyst, or kidney volume. We also determined whether clinical symptoms correlated with t